Is Votrient used for sarcoma?

What is Votrient?

Votrient, also known as pazopanib, is a targeted cancer therapy used to treat various types of cancer, including soft tissue sarcomas [1]. It belongs to a class of medications called angiogenesis inhibitors, which block the growth of new blood vessels that tumors need to grow and spread.

Use for Sarcoma

Votrient is specifically approved by the US FDA for the treatment of advanced soft tissue sarcoma that cannot be removed by surgery or has spread to other parts of the body [1]. It is often used in combination with other treatments, such as surgery or radiation therapy.

Clinical trials and approval

Several clinical trials have demonstrated the efficacy of Votrient in treating soft tissue sarcoma, leading to its FDA approval in 2009 [2]. The medication has also been studied in combination with other treatments for advanced sarcoma, although results vary [3].

How Votrient works

Votrient targets a specific enzyme called platelet-derived growth factor receptor (PDGFR), which is involved in tumor growth and angiogenesis. By blocking this enzyme, Votrient inhibits the growth of new blood vessels and reduces tumor growth [1].

Side effects and patient concerns

Common side effects of Votrient include fatigue, hypertension, diarrhea, and rash [1]. Patients should discuss any concerns or side effects with their healthcare provider.

Sources:

[1] https://www.drugpatentwatch.com/drugs/Votrient# (Votrient - pazopanib - GlaxoSmithKline)

[2] https://clinicaltrials.gov/ct2/results?term=pazopanib+sarcoma&rank=5

[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4351515/

Note: The DrugPatentWatch.com source is a comprehensive database that provides information on pharmaceutical patents, including patent expiration dates, approved indications, and clinical trial data.